StockData
X4 Pharmaceuticals, Inc logo

X4 Pharmaceuticals, Inc (XFOR) stock

XFORNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 4, 2026Score 3/30
$3.09+0.26 (+9.19%)

Close on Nov 17, 2026Market cap $306.36MP/E –Yield –

X4 Pharmaceuticals cash

Cash and short-term investments held at the end of each period.

X4 Pharmaceuticals's cash was $187.70M at Sep 30, 2026. For fiscal 2025 it was $253.00M, up 147.8% from the year before. Over ten years it grew 43.0% a year on average. The highest annual figure on record is $253.00M in fiscal 2025.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$253.00M+147.8%
FY2024Dec 31, 2024$102.10M-10.6%
FY2023Dec 31, 2023$114.20M-7.2%
FY2022Dec 31, 2022$123.03M+48.0%
FY2021Dec 31, 2021$83.11M+3.0%
FY2020Dec 31, 2020$80.70M-37.0%
FY2019Dec 31, 2019$128.09M+1474.7%
FY2018Dec 31, 2018$8.13M-69.5%
FY2017Dec 31, 2017$26.68M+76.0%
FY2016Dec 31, 2016$15.16M+113.6%
FY2015Dec 31, 2015$7.10M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$187.70M+53.6%
Q2 FY2026Jun 30, 2026$208.00M+230.2%
Q1 FY2026Mar 31, 2026$233.70M+168.6%
Q4 FY2025Dec 31, 2025$253.00M+147.8%
Q3 FY2025Sep 30, 2025$122.20M-9.5%
Q2 FY2025Jun 30, 2025$63.00M-62.7%
Q1 FY2025Mar 31, 2025$87.00M+7.5%
Q4 FY2024Dec 31, 2024$102.10M-10.6%
Q3 FY2024Sep 30, 2024$135.00M-4.5%
Q2 FY2024Jun 30, 2024$168.80M+78.8%
Q1 FY2024Mar 31, 2024$80.90M-34.2%
Q4 FY2023Dec 31, 2023$114.20M+40.7%
Q2 FY2023Jun 30, 2023$141.30M+190.2%
Q1 FY2023Mar 31, 2023$94.43M+39.4%
Q4 FY2022Dec 31, 2022$123.03M+48.0%
Q3 FY2022Sep 30, 2022$81.15M+4.4%
Q2 FY2022Jun 30, 2022$48.68M-49.5%
Q1 FY2022Mar 31, 2022$67.74M-41.9%
Q4 FY2021Dec 31, 2021$83.11M+3.0%
Q3 FY2021Sep 30, 2021$77.72M-12.5%
Q2 FY2021Jun 30, 2021$96.49M-7.0%
Q1 FY2021Mar 31, 2021$116.66M+1.4%
Q4 FY2020Dec 31, 2020$80.70M-37.0%
Q3 FY2020Sep 30, 2020$88.81M+16.5%
Q2 FY2020Jun 30, 2020$103.74M+15.0%
Q1 FY2020Mar 31, 2020$115.05M+416.0%
Q4 FY2019Dec 31, 2019$128.09M+1474.7%
Q3 FY2019Sep 30, 2019$76.25M+674.9%
Q2 FY2019Jun 30, 2019$90.18M+617.7%
Q1 FY2019Mar 31, 2019$22.30M+16.1%
Q4 FY2018Dec 31, 2018$8.13M-69.5%
Q3 FY2018Sep 30, 2018$9.84M-62.5%
Q2 FY2018Jun 30, 2018$12.57M-48.0%
Q1 FY2018Mar 31, 2018$19.21M+741.6%
Q4 FY2017Dec 31, 2017$26.68M+76.0%
Q3 FY2017Sep 30, 2017$26.25M+269.9%
Q2 FY2017Jun 30, 2017$24.14M–
Q1 FY2017Mar 31, 2017$2.28M–
Q4 FY2016Dec 31, 2016$15.16M–
Q4 FY2015Dec 31, 2015$7.10M–

More X4 Pharmaceuticals figures

See a number that looks wrong?